Biotechnology

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

March 15, 2022 2:05 PM

Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing. KELOWNA, BC / ACCESSWIRE / March 15, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that the first phase of its...

Read more

CB Scientific, Inc. Concludes its Annual Audit with MaloneBailey, LLP

March 15, 2022 6:00 AM

Achieving Major Milestone Squarely Positions the Company for Uplisting to the OTCQB® Venture Market ESCONDIDO, CA / ACCESSWIRE / March 15, 2022 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that MaloneBailey, LLP has successfully concluded its annual audit of the Company in accordance with Public Company Accounting Oversight Board standards, and consequently issued their favorable Auditor's Report on March 14,...

Read more

Q3 Interim Report - Launch in US with own CLIA Laboratory

March 15, 2022 3:30 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 15, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) SEK 000s Q3 21/22 Q3 20/21 May-Jan 21/22 May-Jan 20/21 Full year 20/21 Net sales 314 1,376 963 1,759 2,077 Operating profit (loss) -14,417 -11,062 -40,970 -28,012 -40,181 Profit (loss) for the period -14,334 -10,909 -40,947 -27,491 -39,482 Earnings per share, after dilution -0.50 -0.38 -1.44 -0.97 -1.39 Significant events during the...

Read more

Biovica Establishes US CLIA Lab to Further Strengthen DiviTum(R)TKa Launch

March 14, 2022 2:10 PM

UPPSALA, SE / ACCESSWIRE / March 14, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces that the company will establish its own US CLIA lab for the launch of DiviTum®TKa on the US market. Biovica aims to have its lab operational and CLIA certified during third quarter 2022. Biovica has decided to establish a CLIA lab in San Diego, California. A location has been identified...

Read more

Black Bird Biotech Enters Agreement with Sales and Marketing Consulting Firm Spire+ to Expedite Brand Growth

March 14, 2022 8:35 AM

Black Bird Biotech Enters Agreement with Sales and Marketing Consulting Firm Spire+ to Expedite Brand Growth FLOWER MOUND, TX / ACCESSWIRE / March 14, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that it entered into a consulting agreement with Spire+, a leading sales and marketing agency that specializes in brand building, marketing, communications and business development....

Read more

Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions

March 14, 2022 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / March 14, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) Enzolytics' ("ENZC") wholly-owned subsidiary Virogentics, Inc. (the "Subsidiary") today announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS. The steps necessary for the production and delivery of the Company's anti-HIV...

Read more

CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

March 11, 2022 5:38 PM

(This release corrects the release that was posted earlier on March 11, 2022 due to the incorrect company logo being added. This release adds the corrected logo) RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces...

Read more

Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

March 11, 2022 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share....

Read more

M2Bio Labs Offers Ketamine IV & Personalized Supercharged Vitamin IV Drip

March 10, 2022 8:55 AM

CAPE TOWN, SA / ACCESSWIRE / March 10, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: M2Bio Sciences is pleased to announce the rollout of its on-site Ketamine and Supercharged Vitamin IV Therapy at the M2Bio Labs in Hout Bay, Cape Town. Drip therapy has long been used in...

Read more

Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month

March 10, 2022 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / March 10, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces that Enzolytics IPF Immune™, its immune modulator, will be introduced into the U.S. market later this month. The product will be presented in late March by the Company's representative Nutritional Products International (https://nutricompany.com/) to large and small retailers at the ECRM's Weight Management, Nutrition, and...

Read more

Michael Hawthorne, PhD, Named Deputy Chief Executive Officer at Bakhu Holdings

March 9, 2022 9:05 AM

LONG BEACH, CA / ACCESSWIRE / March 9, 2022 / Bakhu Holdings, Corp. (OTC PINK:BKUH) today announced the appointment of Michael R. Hawthorne, PhD, 47, as Deputy Chief Executive Officer to primarily assist President and CEO Evripides Drakos in the Company's expansion plans. "Dr. Hawthorne is an international biopharma leader with strategic and operational skills ranging from launching start-up discovery biotech companies up to driving growth in...

Read more

EV Biologics Updates on FINRA Filings

March 9, 2022 9:00 AM

NASHVILLE, TN / ACCESSWIRE / March 9, 2022 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with the latest information about its submitted FINRA applications for name change and NFT dividend distribution. The Company announced on August 6, 2020, that it had submitted its name change filing with FINRA. The Company had previously moved its domicile from Cayman Islands to Wyoming on April 12, 2019 and received its new CUSIP number on...

Read more

One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery

March 9, 2022 8:35 AM

- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation - The VenoValve is currently being evaluated in ongoing SAVVE U.S pivotal trial as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI) IRVINE, CA / ACCESSWIRE / March 9, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a...

Read more

BioInvent and Transgene Announce Poster Presentation on BT-001, a Novel Antibody-Encoding Oncolytic Virus, at AACR 2022

March 8, 2022 5:20 PM

Preclinical Data Shows the Robust Anti-Tumoral Activity of BT-001, Including Its Highly Effective and Safe Therapeutic Strategy of Targeting CLTA-4 LUND, SE / ACCESSWIRE / March 8, 2022 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech...

Read more

BioInvent's BI-1607 to Extend Reach of Anti-FcyRIIB Approach to Breast Cancer

March 8, 2022 5:05 PM

Preclinical Proof of Concept for Second Anti-FcyRIIB Antibody BI-1607 to be Presented at AACR LUND, SE / ACCESSWIRE / March 8, 2022 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the company will be presenting the first data for BI-1607 at the forthcoming annual...

Read more

BioInvent AACR Data Boost Prospects for BI-1808

March 8, 2022 4:50 PM

LUND, SE / ACCESSWIRE / March 8, 2022 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that data regarding the anti-TNFR2 drug candidate BI-1808, currently in clinical development, will be presented at the forthcoming annual meeting of...

Read more

Lexaria Granted Important New Oral Nicotine Patent

March 8, 2022 9:15 AM

Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted a new patent entitled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof". The new Australian patent expands upon Lexaria's international intellectual property...

Read more

The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial

March 8, 2022 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational immunotherapy treatment for patients with glioblastoma (GBM), the deadliest form of brain cancer. Pritumumab (PTB) is a unique monoclonal antibody that attacks cancers originating in the cells lining an organ - referred to as epithelial cells. These include...

Read more

Oxford Nanopore Technologies plc Announces Publication: Nanopore IDs >50 Genetic Diseases

March 8, 2022 2:00 AM

Researchers Use Oxford Nanopore Technology To Develop a Single Test Method To Characterise More Than 50 Genetic Diseases In a Study Published in Science Advances, a Team From the Garvan Institute of Medical Research, Australia, Has Described How Their Method Using Nanopore Sequencing Technology Has the Potential To Reduce the ‘Diagnostic Odyssey' for People With Rare Neurological and Neuromuscular Disease OXFORD, UK / ACCESSWIRE / March 8, 2022...

Read more

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)

March 4, 2022 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 / American CryoStem Corporation (OTC PINK:CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced today that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome (PCS). The Company's autologous mesenchymal stem cell infusion...

Read more